Top

Published in:

01-03-2013

Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature

Authors: Ali A. Valika, Mihai Gheorghiade

Published in: Heart Failure Reviews | Issue 2/2013

Abstract

Heart failure syndromes are often associated with multi-organ dysfunction, and concomitant liver, renal, and neurologic involvement is very common. Neuro-hormonal antagonism plays a key role in the management of this syndrome, and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are one of the cornerstones of therapy. Cardiorenal physiology is becoming more recognized in these patients with advanced heart failure, and the role of neuro-hormonal blockade in this setting is vaguely defined in the literature. Often, angiotensin-converting enzyme inhibitors are decreased or even withheld in these circumstances. The purpose of this article is to review the role and pathophysiology of ace inhibition and angiotensin receptor blockade in patients with acute and chronic heart failure syndromes and concomitant cardiorenal physiology.

Hall JE et al (1977) Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 233(5):F366–F372PubMed

Ainscough JF et al (2009) Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction. Cardiovasc Res 81(3):592–600PubMedCrossRef

Ruggenenti P, Remuzzi G (2011) Worsening kidney function in decompensated heart failure: treat the heart, don’t mind the kidney. Eur Heart J 32(20):2476–2478PubMedCrossRef

Enseleit F, Hurlimann D, Luscher TF (2001) Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 37(Suppl 1):S21–S30PubMedCrossRef

Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160(5):685–693PubMedCrossRef

Ljungman S, Kjekshus J, Swedberg K (1992) Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 70(4):479–487PubMedCrossRef

Swedberg K, Kjekshus J, Snapinn S (1999) Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 20(2):136–139PubMedCrossRef

Blair JE et al (2011) Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J 32(20):2563–2572PubMedCrossRef

Oster JR, Materson BJ (1992) Renal and electrolyte complications of congestive heart failure and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med 152(4):704–710PubMedCrossRef

10.

Packer M et al (1987) Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med 106(3):346–354PubMed

11.

The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349(9069):1857–1863CrossRef

12.

Ruggenenti P, Perna A, Remuzzi G (2001) ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril efficacy in nephropathy. J Am Soc Nephrol 12(12):2832–2837PubMed

13.

Hou FF et al (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354(2):131–140PubMedCrossRef

14.

Klahr S et al (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 330(13):877–884PubMedCrossRef

15.

Jafar TH et al (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139(4):244–252PubMed

16.

Carr AA et al (2005) Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 96(11):1530–1536PubMedCrossRef

17.

Berl T et al (2003) Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138(7):542–549PubMed

18.

Ahluwalia SC et al (2011) Change in comorbidity prevalence with advancing age among persons with heart failure. J Gen Intern Med 26(10):1145–1151PubMedCrossRef

19.

Badve SV et al (2011) Effects of Beta-adrenergic antagonists in patients with chronic kidney disease a systematic review and meta-analysis. J Am Coll Cardiol 58(11):1152–1161PubMedCrossRef

20.

Chang TI, Chertow GM (2011) Chronic kidney disease and cardiovascular therapeutics time to close the evidence gaps. J Am Coll Cardiol 58(11):1162–1164PubMedCrossRef

21.

Desai AS et al (2007) Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM program. J Am Coll Cardiol 50(20):1959–1966PubMedCrossRef

22.

Anand IS et al (2009) Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 120(16):1577–1584PubMedCrossRef

23.

McAlister FA et al (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109(8):1004–1009PubMedCrossRef

24.

Zannad F et al (2006) Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70(7):1318–1324PubMedCrossRef

25.

Cice G et al (2010) Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol 56(21):1701–1708PubMedCrossRef

26.

Motwani JG et al (1992) Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure. Circulation 86(2):439–445PubMedCrossRef

Title: Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature
Authors: Ali A. Valika
Mihai Gheorghiade
Publication date: 01-03-2013
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2013
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-011-9295-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

Incretins as a novel therapeutic strategy in patients with diabetes and heart failure

Heart failure among South Asians: a narrative review of risk, nature, outcomes and management

Uric acid in heart failure: a biomarker or therapeutic target?

Rodent models of heart failure: an updated review

Prognostic implications of renal dysfunction in patients hospitalized with heart failure: data from the last decade of clinical investigations

Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure